大麻化合物：一种治疗帕金森病的非传统方法。
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.
作者信息
Babayeva Mariana, Assefa Haregewein, Basu Paramita, Chumki Sanjeda, Loewy Zvi
机构信息
Touro College of Pharmacy, 230 West 125th Street, Room 530, New York, NY 10027, USA.
出版信息
Parkinsons Dis. 2016;2016:1279042. doi: 10.1155/2016/1279042. Epub 2016 Dec 5.
Abstract
Parkinson's disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States. Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons. The current treatment is symptomatic and mainly involves replacement of dopamine deficiency. This therapy improves only motor symptoms of Parkinson's disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet need for more comprehensive approach in the management of PD. Cannabis and related compounds have created significant research interest as a promising therapy in neurodegenerative and movement disorders. In this review we examine the potential benefits of medical marijuana and related compounds in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease. The potential for cannabis to enhance the quality of life of Parkinson's patients is explored.
摘要
帕金森病（PD）是一种神经退行性疾病，是美国第二常见的神经系统疾病。在神经学上，它的特征是一组独特的细胞——黑质纹状体多巴胺神经元选择性退化。目前的治疗是对症治疗，主要涉及补充多巴胺缺乏。这种疗法仅改善帕金森病的运动症状，并且伴有包括运动障碍在内的多种不良反应。因此，在帕金森病的管理方面，对更全面方法的需求尚未得到满足。大麻及相关化合物作为神经退行性疾病和运动障碍的一种有前景的疗法，引起了大量研究兴趣。在本综述中，我们研究了医用大麻及相关化合物在治疗运动和非运动症状以及减缓疾病进展方面的潜在益处。探讨了大麻改善帕金森病患者生活质量的可能性。
相似文献
1
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.大麻化合物：一种治疗帕金森病的非传统方法。
Parkinsons Dis. 2016;2016:1279042. doi: 10.1155/2016/1279042. Epub 2016 Dec 5.
2
Pros and Cons of Marijuana in Treatment of Parkinson's Disease.大麻用于治疗帕金森病的利弊
Cureus. 2019 Jun 3;11(6):e4813. doi: 10.7759/cureus.4813.
3
Marijuana for Parkinson's Disease?大麻用于治疗帕金森病？
Innov Clin Neurosci. 2019 Jan 1;16(1-2):33-34.
4
Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.尼古丁与烟碱受体药物：对帕金森病及药物性运动障碍的潜在作用
Int Rev Neurobiol. 2015;124:247-71. doi: 10.1016/bs.irn.2015.07.005. Epub 2015 Aug 18.
5
Parkinson's Disease: A Current Perspectives on Parkinson's Disease and Key Bioactive Natural Compounds as Future Potential Drug Candidates.帕金森病：关于帕金森病的当前观点以及作为未来潜在候选药物的关键生物活性天然化合物
Curr Drug Targets. 2022;23(1):2-20. doi: 10.2174/1389450122666210623115505.
6
Parkinson's disease: Autoimmunity and neuroinflammation.帕金森病：自身免疫与神经炎症。
Autoimmun Rev. 2016 Oct;15(10):1005-11. doi: 10.1016/j.autrev.2016.07.022. Epub 2016 Aug 4.
7
Parkinson's disease: Diagnosis and appreciation of comorbidities.帕金森病：合并症的诊断与评估
Handb Clin Neurol. 2019;167:257-277. doi: 10.1016/B978-0-12-804766-8.00014-5.
8
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.帕金森病患者左旋多巴相关运动并发症的药物治疗
CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005.
9
New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease.帕金森病运动和非运动症状管理的新对症治疗方法。
Int Rev Neurobiol. 2017;132:407-452. doi: 10.1016/bs.irn.2017.03.004. Epub 2017 May 16.
10
Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life.帕金森病多模态综合治疗改善运动症状、抑郁和生活质量。
J Neurol. 2020 Apr;267(4):954-965. doi: 10.1007/s00415-019-09657-7. Epub 2019 Dec 3.
引用本文的文献
1
Low doses of cannabis extract ameliorate non-motor symptoms of Parkinson's disease patients: a case series.低剂量大麻提取物改善帕金森病患者的非运动症状：病例系列
Front Hum Neurosci. 2025 Feb 24;18:1466438. doi: 10.3389/fnhum.2024.1466438. eCollection 2024.
2
Cannabinoids' Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases.大麻素在神经退行性疾病中调节中枢和外周免疫的作用。
Int J Mol Sci. 2024 Jun 10;25(12):6402. doi: 10.3390/ijms25126402.
3
Non-linear plasma protein binding of cannabidiol.大麻二酚的非线性血浆蛋白结合
J Cannabis Res. 2024 Jun 20;6(1):27. doi: 10.1186/s42238-024-00238-8.
4
Marijuana's potential in neurodegenerative diseases: an editorial.大麻在神经退行性疾病中的潜力：一篇社论。
AIMS Neurosci. 2023 Jun 25;10(2):175-177. doi: 10.3934/Neuroscience.2023014. eCollection 2023.
5
Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease.帕金森病冻结步态的未来治疗策略
Front Hum Neurosci. 2021 Nov 2;15:741918. doi: 10.3389/fnhum.2021.741918. eCollection 2021.
6
Receptor-Dependent and Independent Regulation of Voltage-Gated Ca Channels and Ca-Permeable Channels by Endocannabinoids in the Brain.脑内内源性大麻素对电压门控钙通道和钙通透通道的受体依赖性和非受体依赖性调节。
Int J Mol Sci. 2021 Jul 29;22(15):8168. doi: 10.3390/ijms22158168.
7
Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US.拨开迷雾：美国帕金森病患者大麻使用情况调查
NPJ Parkinsons Dis. 2021 Mar 3;7(1):21. doi: 10.1038/s41531-021-00165-y.
8
Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.大麻素受体和配体：中枢神经系统疾病的启示与新型治疗方法的探索。
Adv Exp Med Biol. 2021;1297:43-64. doi: 10.1007/978-3-030-61663-2_4.
9
L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment.左洛复作为一种符合多靶点治疗标准的天然药物。
Int J Mol Sci. 2021 Jan 14;22(2):778. doi: 10.3390/ijms22020778.
10
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.内源性大麻素信号在帕金森病中作用的特征证据：相关治疗干预的视角。
Int J Mol Sci. 2020 Aug 28;21(17):6235. doi: 10.3390/ijms21176235.
本文引用的文献
1
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.脂肪酸酰胺水解酶抑制作用治疗帕金森病的症状缓解。
Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16.
2
CB cannabinoid receptor-mediated anandamide signalling reduces the defensive behaviour evoked through GABA receptor blockade in the dorsomedial division of the ventromedial hypothalamus.CB大麻素受体介导的花生四烯酸乙醇胺信号传导减少了通过腹内侧下丘脑背内侧区GABA受体阻断所诱发的防御行为。
Neuropharmacology. 2017 Feb;113(Pt A):156-166. doi: 10.1016/j.neuropharm.2016.04.003. Epub 2016 Apr 8.
3
The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.免疫系统和神经炎症作为阿尔茨海默病、帕金森病和亨廷顿病血液生物标志物的潜在来源。
ACS Chem Neurosci. 2016 May 18;7(5):520-7. doi: 10.1021/acschemneuro.6b00042. Epub 2016 Apr 14.
4
Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets.脂肪酸酰胺水解酶催化中脂质选择的关键：结构灵活性、门控残基和多个结合口袋。
PLoS Comput Biol. 2015 Jun 25;11(6):e1004231. doi: 10.1371/journal.pcbi.1004231. eCollection 2015 Jun.
5
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.医用大麻治疗慢性疼痛及其他医学和精神疾病：临床综述。
JAMA. 2015;313(24):2474-83. doi: 10.1001/jama.2015.6199.
6
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.基于大麻素的帕金森病治疗前景：从运动症状到神经保护
Mol Neurodegener. 2015 Apr 8;10:17. doi: 10.1186/s13024-015-0012-0.
7
Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.科罗拉多州帕金森病患者自述大麻及其他补充医学疗法的疗效
Evid Based Complement Alternat Med. 2015;2015:874849. doi: 10.1155/2015/874849. Epub 2015 Mar 2.
8
Monoamine reuptake inhibitors in Parkinson's disease.单胺再摄取抑制剂在帕金森病中的应用。
Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.
9
An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.罗替戈汀透皮系统在帕金森病和不宁腿综合征中的药理学、药代动力学特性及药物相互作用的最新进展。
Drugs. 2015 Apr;75(5):487-501. doi: 10.1007/s40265-015-0377-y.
10
Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.油酸乙醇酰胺的全身给药可保护大鼠免受脂多糖诱导的神经炎症和快感缺失的影响。
Int J Neuropsychopharmacol. 2014 Dec 28;18(6):pyu111. doi: 10.1093/ijnp/pyu111.
Zotero 插件